APA (7th ed.) Citation

MS, E., MM, R., X, Y., K, H., Y, L., TL, G., . . . R, Y. (2026). Measuring the health benefits and costs of antimicrobial-resistant gonorrhea surveillance in the United States: An agent-based model and cost-effectiveness analysis. Lancet regional health. Americas, 62, 101582. https://doi.org/10.1016/j.lana.2026.101582

Chicago Style (17th ed.) Citation

MS, Ekanayake-Weber, et al. "Measuring the Health Benefits and Costs of Antimicrobial-resistant Gonorrhea Surveillance in the United States: An Agent-based Model and Cost-effectiveness Analysis." Lancet Regional Health. Americas 62 (2026): 101582. https://doi.org/10.1016/j.lana.2026.101582.

MLA (9th ed.) Citation

MS, Ekanayake-Weber, et al. "Measuring the Health Benefits and Costs of Antimicrobial-resistant Gonorrhea Surveillance in the United States: An Agent-based Model and Cost-effectiveness Analysis." Lancet Regional Health. Americas, vol. 62, 2026, p. 101582, https://doi.org/10.1016/j.lana.2026.101582.